Mepolizumab, sold under the brand name Nucala by GlaxoSmithKline, is a humanized monoclonal antibody used for the treatment of severe eosinophilic asthma... 14 KB (1,145 words) - 06:41, 10 April 2024 |
 | eosinophils in blood are rapidly reduced monoclonal antibody therapy – e.g., mepolizumab or reslizumab against IL-5, prevents eosinophilopoiesis, or benralizumab... 27 KB (2,943 words) - 06:43, 6 April 2024 |
 | with polyangiitis. Patients taking mepolizumab experienced a "significant improvement" in their symptoms. Mepolizumab is a monoclonal antibody that targets... 28 KB (2,682 words) - 05:26, 13 March 2024 |
 | glucocorticoids such as prednisone. The addition of the monoclonal antibody mepolizumab may reduce the dose of glucocorticoids. Depending on eosinophil target-organ... 26 KB (2,491 words) - 00:06, 7 February 2024 |
 | diets to avoid food allergies, azathioprine and antibodies, including mepolizumab, omalizumab, infliximab, and adalimumab. The word enteritis (/ˌɛntəˈraɪtɪs/)... 19 KB (1,909 words) - 11:30, 29 April 2024 |
(naratriptan hydrochloride) Nimbex (cisatracurium besilate) Nucala (mepolizumab) Ojjaara (momelotinib) Otosporin ear drops (polymyxin B sulphate, neomycin... 7 KB (628 words) - 18:58, 27 December 2023 |
 | options with oral corticosteroids, biological treatments (e.g. omalizumab, mepolizumab) or allergen immunotherapy. Eczema Asthma Rhinitis Anaphylaxis Allergic... 24 KB (2,561 words) - 06:47, 11 January 2024 |
helminthic therapy; a drug to suppress toll-like receptor 9 (TLR9); and mepolizumab to treat eosinophilic esophagitis. Penicillin desensitization editor... 3 KB (407 words) - 17:15, 15 December 2020 |
 | market in recent years have been used to treat AERD including dupilumab, mepolizumab, omalizumab, and benralizumab. Among treatment options, biologics have... 50 KB (5,530 words) - 00:27, 18 April 2024 |
 | beyond one year are unknown. Monoclonal antibody injections such as mepolizumab, dupilumab, or omalizumab may be useful in those with poorly controlled... 167 KB (18,053 words) - 09:27, 28 April 2024 |
 | Agonists: Interleukin 5 Antagonists: YM-90709 Antibodies: Benralizumab Mepolizumab Reslizumab Antisense oligonucleotides: TPI ASM8 IL-6 Agonists: Atexakin... 22 KB (1,841 words) - 22:50, 30 April 2024 |
there are two FDA-approved monoclonal antibodies that inhibit IL-5, mepolizumab and reslizumab. Additionally, the antibody benralizumab blocks the interleukin-5... 13 KB (1,478 words) - 06:37, 13 March 2024 |
 | in order to alleviate symptoms. Some examples of these drugs include mepolizumab, reslizumab, and benralizumab. Although eosinopenia has long been recognized... 15 KB (1,693 words) - 15:08, 25 April 2024 |
mepiroxol (INN) mepitiostane (INN) mepivacaine (INN) mepixanox (INN) mepolizumab (INN) mepramidil (INN) meprednisone (INN) Mepriam Mepro-Aspirin meprobamate... 5 KB (276 words) - 15:41, 20 March 2022 |
 | inflammatory phenotype and the eosinophilic inflammatory phenotype. Mepolizumab, a monoclonal antibody, has been shown to have benefit in treating the... 157 KB (17,022 words) - 03:53, 30 April 2024 |
2009, Firestone researchers demonstrated that an experimental drug, mepolizumab can help reduce eosinophil production in sufferers of severe asthma.... 5 KB (524 words) - 21:11, 4 January 2024 |
blockers: Altrakincept Pascolizumab IL-5-specific blockers: Benralizumab Mepolizumab Reslizumab IL-13-specific blockers: Lebrikizumab Tralokinumab Dual IL-4... 5 KB (560 words) - 21:43, 1 April 2024 |
Agonists: Interleukin 5 Antagonists: YM-90709 Antibodies: Benralizumab Mepolizumab Reslizumab Antisense oligonucleotides: TPI ASM8 IL-6 Agonists: Atexakin... 25 KB (1,922 words) - 02:45, 30 April 2024 |
 | Agonists: Interleukin 5 Antagonists: YM-90709 Antibodies: Benralizumab Mepolizumab Reslizumab Antisense oligonucleotides: TPI ASM8 IL-6 Agonists: Atexakin... 15 KB (1,152 words) - 06:14, 7 April 2024 |
Agonists: Interleukin 5 Antagonists: YM-90709 Antibodies: Benralizumab Mepolizumab Reslizumab Antisense oligonucleotides: TPI ASM8 IL-6 Agonists: Atexakin... 12 KB (1,289 words) - 19:20, 4 December 2023 |
Agonists: Interleukin 5 Antagonists: YM-90709 Antibodies: Benralizumab Mepolizumab Reslizumab Antisense oligonucleotides: TPI ASM8 IL-6 Agonists: Atexakin... 5 KB (267 words) - 03:30, 20 April 2024 |
 | Agonists: Interleukin 5 Antagonists: YM-90709 Antibodies: Benralizumab Mepolizumab Reslizumab Antisense oligonucleotides: TPI ASM8 IL-6 Agonists: Atexakin... 24 KB (2,070 words) - 07:13, 15 March 2024 |
 | Agonists: Interleukin 5 Antagonists: YM-90709 Antibodies: Benralizumab Mepolizumab Reslizumab Antisense oligonucleotides: TPI ASM8 IL-6 Agonists: Atexakin... 49 KB (6,005 words) - 11:09, 8 February 2024 |
Sirukumab Spesolimab Tildrakizumab Tocilizumab Ustekinumab Interleukin 5 Mepolizumab Immunoglobulin E Omalizumab Interferon Faralimomab IL-6 Elsilimomab IL-12... 7 KB (299 words) - 13:45, 27 April 2024 |
 | Agonists: Interleukin 5 Antagonists: YM-90709 Antibodies: Benralizumab Mepolizumab Reslizumab Antisense oligonucleotides: TPI ASM8 IL-6 Agonists: Atexakin... 19 KB (2,293 words) - 11:05, 8 March 2024 |
Agonists: Interleukin 5 Antagonists: YM-90709 Antibodies: Benralizumab Mepolizumab Reslizumab Antisense oligonucleotides: TPI ASM8 IL-6 Agonists: Atexakin... 16 KB (1,451 words) - 21:00, 23 April 2024 |
 | Agonists: Interleukin 5 Antagonists: YM-90709 Antibodies: Benralizumab Mepolizumab Reslizumab Antisense oligonucleotides: TPI ASM8 IL-6 Agonists: Atexakin... 43 KB (4,990 words) - 05:37, 29 April 2024 |
 | Agonists: Interleukin 5 Antagonists: YM-90709 Antibodies: Benralizumab Mepolizumab Reslizumab Antisense oligonucleotides: TPI ASM8 IL-6 Agonists: Atexakin... 21 KB (2,761 words) - 19:32, 11 April 2024 |
Agonists: Interleukin 5 Antagonists: YM-90709 Antibodies: Benralizumab Mepolizumab Reslizumab Antisense oligonucleotides: TPI ASM8 IL-6 Agonists: Atexakin... 14 KB (1,017 words) - 05:42, 14 April 2024 |
eosinophilic granulomatosis with polyangiitis can be successfully treated with mepolizumab. Idiopathic hypereosinphilic syndrome and lymphocyte-variant hypereosinophilia:... 32 KB (3,618 words) - 03:33, 3 December 2023 |